Insider buying last 90 days
No open-market insider purchases were filed for LMAT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every LMAT insider filing, plotted on the chart in Gekko.Open LMAT in Gekko
NASDAQ: LMAT
LeMaitre Vascular (LMAT) Stock Analysis & Forecast
Oct 12 close
$82.91+2.22 (+2.8%)
Gekko Brief
AI summaryOct 12 closeLeMaitre Vascular confirmed it will report third-quarter 2026 earnings on 5 November 2026, after market close, with analysts anticipating $0.6860 per share on revenues of $67.39 million. Attention this week also centered on analyst activity following the prior quarter: Argus lowered its target price to $87.00 while Barrington maintained a Buy rating with a $95.00 price target, both referencing Q2 sales of $70.38 million, up 9.60% year over year, alongside diluted earnings per share of $0.74 that missed the $0.81 consensus estimate.
Shares closed at $82.91, up 2.8%, sitting between the 50-day average of $81.74 and the 200-day average of $94.48. Over the past month the stock gained 2.9%, though it remains down 15.3% over three months, 28% over six months, and 5.1% over the past year. The GekkoIndex reads 56.4, placing it in the Neutral zone, down 3.5 over the last five sessions. Price stands 11.8% below Gekko Fair Value of $94.02.
Earnings on 5 November fall within the next 20 trading days, a period in which the stock's historical seasonality shows an average move of -1.6% over five years, rising in 3 of those years. The prior earnings reaction was a decline of 23.8%, with an average absolute move of 11.5% across the last eight quarters. No insider, Congress or unusual options activity appears in the current windows, leaving the upcoming report as the main scheduled catalyst.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
LeMaitre Vascular price vs fair value
Close $82.91200-day averageGekko Fair Value $94.02
LeMaitre Vascular quick facts
- Market cap
- $1.89B
- P/E ratio
- 27.9
- Forward P/E
- 25.6
- EPS, TTM
- $2.85
- Revenue, TTM
- $262.4M
- Profit margin
- 25%
- Dividend yield
- 1.13%
- Beta
- 0.47
- Volume
- 257,854 avg 263,491
- 1-year return
- −5.1%
- Typical daily move
- ±2.7%
- Typical 20-day move
- ±5.4%
- 50-day average
- $81.74
- 200-day average
- $94.48
- Next earnings
- Nov 5 after close
- Shares outstanding
- 22.87M
LeMaitre Vascular swing-trade checklist
LeMaitre Vascular scores 1 supportive, 3 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive3 mixed1 headwind
- Trendmixed
Averages disagree
Close $82.91 sits between the 50-day ($81.74) and 200-day ($94.48) averages, or the averages disagree.
See the chart - GekkoIndexmixed
56.4, Neutral
Reading 56.4 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
11.8% below
Price is 11.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
−1.6% on average
From this point in the calendar, the next 20 trading days averaged −1.6% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
LeMaitre Vascular stock chart and price history
LeMaitre Vascular closed at $82.91 on Oct 12, 2026, −5.1% over the past year, inside a 52-week range of $78.22 to $118.01.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +2.9%
- 3 months
- −15.3%
- 6 months
- −28.0%
- 1 year
- −5.1%
The full LMAT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open LMAT in Gekko
Follow LeMaitre Vascular through every session
Put LMAT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track LMAT in GekkoFree for 7 days. No credit card required.
About LeMaitre Vascular
LeMaitre Vascular makes and distributes medical devices and implants used to treat peripheral vascular disease, serving physicians and hospitals worldwide. It is known for a broad line of specialized catheters, among them angioscopes for viewing inside blood vessels, embolectomy catheters for clearing clots, occlusion catheters that pause blood flow, perfusion catheters for delivering fluids, and thrombectomy catheters with a balloon design for removing venous clots.
Beyond catheters, the company supplies carotid shunts used to maintain blood flow to the brain during artery-clearing surgery, radiopaque tape that helps surgeons map skin sites to underlying vessels, valvulotomes for preparing a vein to serve as a bypass graft, vascular grafts to replace damaged arteries, patches for closing vessels after surgery, and clip-based closure systems that offer an alternative to stitching. These products reach customers through its own sales staff as well as outside distributors.
The company began in 1983 under the name Vascutech, Inc. and took the LeMaitre Vascular name in April 2001. It is based in Burlington, Massachusetts, and its shares trade on the NASDAQ under the ticker LMAT.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- lemaitre.com
LeMaitre Vascular GekkoIndex: the smart money zone
LeMaitre Vascular’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 56.4, in the Neutral zone, down 3.5 points over five sessions.
56.4Neutral
Down 3.5 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 27 | +2.3% | +2.0% | ||
| Accumulation | 217 | +0.5% | +3.5% | ||
| Neutral (current zone) | 386 | +0.1% | +0.4% | ||
| Distribution | 46 | +1.2% | +0.3% | ||
| Selling | 6 | Too few readings yet | |||
Average LMAT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the LMAT price, zone by zone.Track LMAT in Gekko
Is LeMaitre Vascular stock overvalued? Gekko Fair Value
LeMaitre Vascular trades 11.8% below Gekko Fair Value of $94.02, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what LeMaitre Vascular shares are worth, recalculated every trading day.
$94.02
Gekko Fair Value, Oct 10, 2026
11.8% Undervalued
At the end of Aug 2026 the price was 19.3% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open LMAT in Gekko
LeMaitre Vascular insider and Congress trading
No open-market insider purchases were filed for LeMaitre Vascular, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in LMAT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for LMAT, plotted on the chart in Gekko.Open LMAT in Gekko
Buybacks
LeMaitre Vascular has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $112K
- As a share of market cap
- 0.01%
From company filings.
LeMaitre Vascular earnings: next date and track record
LeMaitre Vascular reports on Nov 5, 2026, after the close (24 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 24 days away
- EPS estimate
- $0.69
- Revenue estimate
- $67.39M
5 of 8reports beat the EPS estimate
±11.5%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 4, 2026 AI summary
- What they said
- LeMaitre Vascular reported Q2 2026 financial results with solid underlying performance driven by strong growth in Artegraft and favorable product mix. Company-wide organic sales grew 10% in Q2 (7% price, 3% units); excluding catheters (down 11% year-over-year due to a recall-driven stocking comp), organic growth was 12% (7% price, 5% units). Artegraft grew 34% and became the largest product category, with international Artegraft sales rising and approvals in several new countries; management now expects Artegraft sales of $11 million in 2026 versus $4 million in 2025. Gross margin expanded to 72.1% (+210 bps) driven by higher ASPs, reduced shipping costs and favorable mix. Operating income was a record $20.4 million (up 26%) and operating margin was 29%; net income rose 24% to $17.1 million and diluted EPS $0.74 (up 23%). Cash and securities totaled $376 million with $16 million cash from operations. Management highlighted initiatives including relocating tissue processing to Burlington, a new high-bay warehouse in Billerica, and a relocalization strategy in Europe that is producing margin benefits. The company underperformed its Q2 sales guidance by $1.1 million due to three drivers: stronger dollar (FX), export delays from the Middle East conflict, and cardiac allograft supply constraints; those three items are expected to continue to hamper H2 sales and contributed to a modest downward adjustment in operating income guidance despite slightly improved gross margin outlook. Management noted potential FDA feedback that may require a clinical trial for Quick Stick/Artegraft Quick Stick, which would be a significant decision and investment. The M&A pipeline is active with additional business development headcount added.
- Guidance
- Artegraft sales expectation: $11 million in 2026 vs $4 million in 2025. Management indicated a modest downward revision to full-year operating income guidance (no specific numeric provided in the transcript) and a slightly higher full-year gross margin expectation; the company said its guidance reflects continued headwinds from FX, Middle East export delays, and cardiac allograft supply constraints in H2 2026.
- Risks flagged
- Currency (stronger dollar) headwind; export disruptions due to Middle East conflict delaying shipments; cardiac allograft supply constraints limiting sales growth; potential requirement from FDA to conduct a clinical trial for Artegraft Quick Stick (regulatory risk); historical recall-related effects (catheter packaging) that created difficult comparables and channel stocking dynamics.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | $0.74 est $0.81 | $70.38M est $71.47M | −23.8% |
| May 5, 2026 | $0.68 est $0.66 | $66.55M est $66.67M | −1.2% |
| Feb 25, 2026 | $0.68 est $0.67 | $64.45M est $62.82M | +25.3% |
| Nov 6, 2025 | $0.62 est $0.56 | $61.05M est $62.18M | +0.6% |
| Aug 5, 2025 | $0.60 est $0.57 | $64.23M est $60.90M | +10.5% |
| May 1, 2025 | $0.48 est $0.50 | $59.87M est $57.61M | −13.3% |
| Feb 27, 2025 | $0.49 est $0.49 | $55.72M est $55.99M | −10.9% |
| Oct 31, 2024 | $0.49 est $0.44 | $54.82M est $55.98M | +6.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
LeMaitre Vascular stock forecast and analyst price targets
Analysts’ average 12-month price target for LeMaitre Vascular is $107.00, +29.1% from the last close, from 4 firms rating the stock in the last 90 days.
$107.00consensus 12-month target, +29.1% from the last close
Now $82.91Avg $107.00
Low $94High $120
Each firm’s latest rating in the last 90 days: 4 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 1 | Barrington | $95 | +14.6% |
| Aug 5 | Barrington | — | — |
| Aug 5 | Stifel Nicolaus | $120 | +44.7% |
| Aug 5 | Wells Fargo | $94 | +13.4% |
| Aug 5 | Wells Fargo | $94 | +13.4% |
+0.4%average 20-day move after past Neutral readings
−1.6%average move over the next 20 trading days in the last 5 years
±2.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
LeMaitre Vascular seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, LeMaitre Vascular averaged −1.6% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.7% | 3 of 5 |
| Next 10 trading days | −1.4% | 3 of 5 |
| Next 15 trading days | −5.9% | 2 of 5 |
| Next 20 trading days | −1.6% | 3 of 5 |
| Next 30 trading days | −1.0% | 2 of 5 |
For scale, LMAT’s typical 20-trading-day move in either direction is about 5.4%.
LeMaitre Vascular market cap and key statistics
LeMaitre Vascular’s market cap is $1.89B, with a P/E ratio of 27.9 and revenue of $262.4M over the last twelve months.
Valuation
- Market cap
- $1.89B
- P/E ratio
- 27.9
- Forward P/E
- 25.6
- EPS, TTM
- $2.85
- Gekko Fair Value
- $94.02
Trading
- Volume
- 257,854
- Avg volume, 20 days
- 263,491
- 52-week high
- $118.01
- 52-week low
- $78.22
- Shares outstanding
- 22.87M
Financials
- Revenue, TTM
- $262.4M
- Profit margin
- 25%
- Return on equity
- 16.8%
- Quarterly earnings growth, YoY
- +22.6%
Risk and income
- Beta
- 0.47
- Typical daily move
- ±2.7%
- Typical 20-day move
- ±5.4%
- Dividend yield
- 1.13%
LeMaitre Vascular stock news this week
Coverage of LeMaitre Vascular this week reads positive: 4 positive, 2 neutral and 0 negative headlines.
- LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026GlobeNewsWire, Oct 12
- LeMaitre Vascular, Inc. (LMAT) Stock ForecastsYahoo! Finance Canada, Oct 11
- LeMaitre Vascular (NASDAQ:LMAT): A Quality Stock for Long-Term InvestorsChartMill, Oct 9
- LeMaitre Vascular Q3 2026 Earnings Date and EstimatesMarketBeat, Oct 9
- LeMaitre Vascular stock costs EUR 70.50 before November resultsAD HOC NEWS, Oct 8
- Do LeMaitre Vascular's (NASDAQ:LMAT) Earnings Warrant Your Attention?Moomoo, Oct 8
LeMaitre Vascular peers
LeMaitre Vascular’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
LeMaitre Vascular stock FAQ
What is LeMaitre Vascular’s market cap?
LeMaitre Vascular’s market cap is $1.89B at the Oct 12, 2026 close of $82.91, with 22.87M shares outstanding. The shares trade on a P/E ratio of 27.9.
What is the LeMaitre Vascular stock forecast?
The consensus analyst 12-month price target for LeMaitre Vascular is $107.00, +29.1% from the last close. Of the 4 firms that rated the stock in the last 90 days, 2 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is LeMaitre Vascular stock overvalued or undervalued?
On Gekko’s estimate LeMaitre Vascular is undervalued: the Oct 12, 2026 close of $82.91 is 11.8% below Gekko Fair Value of $94.02. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does LeMaitre Vascular report earnings next?
LeMaitre Vascular is expected to report on Nov 5, 2026, after the market closes (24 days away). Analysts expect earnings of $0.69 per share on revenue of $67.39M. LeMaitre Vascular beat the earnings estimate in 5 of its last 8 reports, moving 11.5% on average across the report.
What is LeMaitre Vascular’s 52-week high and low?
LeMaitre Vascular’s 52-week high is $118.01 and its 52-week low is $78.22; it closed at $82.91 on Oct 12, 2026, −5.1% over the past year.
Is LeMaitre Vascular stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (fair value), 3 as mixed (trend, gekkoindex and seasonality) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See LeMaitre Vascular the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.